Core Viewpoint - The approval of Ryaltris® (GSP 301 NS) by the National Medical Products Administration marks a significant milestone for the company and the introduction of a new treatment option for allergic rhinitis in China, leading the market towards a combination therapy era [1][2]. Group 1: Product Approval and Market Impact - Ryaltris® is a novel combination nasal spray for the treatment of moderate to severe allergic rhinitis in adults and children aged 6 and above, providing a more convenient and effective treatment option [2]. - The market for allergic rhinitis medications in China is projected to grow from 43.275 billion yuan in 2024 to 50.090 billion yuan in 2028, with a compound annual growth rate of approximately 3.72% [1]. - Prior to Ryaltris®, there were no approved combination nasal sprays in China, and existing single-agent nasal sprays were primarily foreign products [1]. Group 2: Company Strategy and Future Development - The successful approval of Ryaltris® is a key milestone for the company's respiratory and critical care segment, showcasing its innovative capabilities in the field of respiratory diseases [2]. - The company is committed to continuing its focus on the research and development of innovative products and advanced technologies, aiming to build a comprehensive product pipeline for chronic airway diseases and critical care [2].

Core Viewpoint - The approval of Ryaltris (GSP301NS) by the National Medical Products Administration marks a significant milestone for the company and the beginning of a new era in the treatment of allergic rhinitis in China, transitioning to a combination therapy approach led by domestic enterprises [1][2]. Group 1: Product Approval and Market Impact - Ryaltris, a combination nasal spray for treating moderate to severe allergic rhinitis in adults and children, has received its drug registration certificate without any supplementary information requests during the review process, achieving a "zero supplementary" approval [1]. - The market for allergic rhinitis medications in China is projected to grow from 43.275 billion yuan in 2024 to 50.090 billion yuan by 2028, with a compound annual growth rate of approximately 3.72% [1]. Group 2: Clinical Significance and Competitive Landscape - Currently, the primary treatments for allergic rhinitis in China are single-agent formulations, but studies indicate that moderate to severe cases often remain uncontrolled even with standard treatments [1]. - Ryaltris has already been approved in several countries, including the United States, Australia, and the European Union, highlighting its international acceptance and potential [2]. Group 3: Company Strategy and Future Development - The successful approval of Ryaltris is a key milestone for the company's respiratory and critical care segment, showcasing its innovation capabilities in the field of respiratory diseases [2]. - The company plans to continue focusing on innovative product development and advanced technology, aiming to create a comprehensive management product cluster for chronic airway diseases and critical care pipelines [2].